rethinkTHC Search
Menu
Study breakdown

Should medicinal cannabis patients face zero-tolerance drug driving laws?

ReviewModerate evidence
The takeaway

A policy analysis from Australia found that zero-tolerance THC driving laws disproportionately harm medicinal cannabis patients, whose road safety risks appear similar to or lower than those taking other legal prescription medications that impair driving.

Medicinal cannabis patients concerned about driving laws, policymakers working on drug driving legislation, and anyone interested in the tensions between cannabis health and traffic policy.

Road risk similar to other prescription drugs

What the researchers found

Road safety risks associated with medicinal cannabis appear similar to or lower than numerous other potentially impairing prescription medications. Zero-tolerance THC laws criminalize patients who test positive for THC even when not impaired and using cannabis as prescribed. Some patients forgo needed medication to maintain driving access, while others face criminal sanctions despite following medical advice.

Why it matters

As countries legalize medical cannabis but maintain zero-tolerance driving laws based on THC detection (not impairment), patients face a cruel choice between medication and mobility. This analysis argues the inconsistency is rooted in cannabis's historical prohibition, not evidence.

The numbers in context

Medical exemptions exist for other impairing drugs like methadone in Australia; THC presence-based offences apply regardless of impairment; comparable jurisdictions have implemented medical exemptions for cannabis

How the study worked

Policy analysis examining Australian regulatory approaches to potentially impairing prescription drugs versus illicit drugs, evidence on cannabis and road safety risk, patient impact data, and international comparisons of medicinal cannabis driving regulations.

What this study cannot tell us

Focused on Australian policy context. Does not provide new empirical data on driving impairment. Arguments rely on existing evidence base, which has limitations around cannabis and driving.

How to read the evidence

Policy analysis synthesizing existing evidence. Arguments are well-supported but this is not a systematic review of driving impairment data.

When this study was published

Published in 2021; several jurisdictions have since updated their medicinal cannabis driving laws.

The bigger picture

The tension between health policy (approving cannabis as medicine) and traffic policy (criminalizing any THC presence) creates an incoherent legal landscape. Other jurisdictions have resolved this through medical exemptions, demonstrating feasible alternatives to the Australian approach.

Questions still open

  • What level of THC correlates with meaningful driving impairment in regular medical users? How do tolerance effects change the risk profile for daily medicinal cannabis patients? Would impairment-based testing be more effective and equitable than presence-based testing?

Common questions

Can medicinal cannabis patients drive?
In some jurisdictions, zero-tolerance laws mean patients can be prosecuted for THC in their system even when not impaired. This analysis argues these laws are inconsistent with how other impairing prescription drugs are regulated.
Is medicinal cannabis more dangerous for driving than other medications?
This analysis found road safety risks from medicinal cannabis appear similar to or lower than many other legal prescription medications that can impair driving, such as opioids and benzodiazepines.

Read the original research

Medicinal cannabis and driving: the intersection of health and road safety policy.

The International journal on drug policy, 97, 103307

Citation

Perkins, Daniel; Brophy, Hugh; McGregor, Iain S; O'Brien, Paula; Quilter, Julia; McNamara, Luke; Sarris, Jerome; Stevenson, Mark; Gleeson, Penny; Sinclair, Justin; Dietze, Paul. (2021). Medicinal cannabis and driving: the intersection of health and road safety policy.. The International journal on drug policy, 97, 103307. https://doi.org/10.1016/j.drugpo.2021.103307